Press Releases
Samsung Biologics’ Sixth Anniversary Ceremony
Samsung Biologics’ Sixth Anniversary Ceremony
- Held on April 21 at Samsung Biologics’ headquarters in Songdo, Incheon, with 300 utives and employees present
- Dr. Tae Han Kim, President and CEO, introduced the vision of becoming a “game changer to expand the CMO market”
?Samsung Biologics (CEO: Tae Han Kim) held its sixth anniversary ceremony on April 21 (Fri), 2017 at its headquarters in Songdo, Incheon.
With 300 utives and employees attending the event, the ceremony started with a commemorative speech by Dr. Kim, who has led Samsung Biologics for 6 years since its establishment, followed by an awards ceremony for exemplary employees who have contributed to the development of the company.
In 2010, Samsung group designated the biopharmaceutical industry as one of five new businesses, and established Samsung Biologics the next year in 2011.
Right after its establishment, Samsung Biologics began constructing its Plant 1 which has a capacity of 30,000L. Then in 2013, Samsung Biologics began construction of its Plant 2, which has a capacity of 150,000L, marking the world’s largest plant in capacity, breaking the world record in the biopharmaceutical industry in terms of production capacity, cost and construction period. In 2015, Samsung Biologics sought to break the world record once again by beginning construction of its Plant 3 with a capacity of 180,000L.
Samsung Biologics has become the largest CMO company in the world by ceaselessly establishing three plants with intensive investment over the past six years. Furthermore, by acquiring quality approvals from the U.S., Europe, and Japan, the top three global pharmaceutical markets, its competitive edge in terms of quality has been proven worldwide in a short period of time.
Based on its quantitative and qualitative growth, the company has sustainably expanded its production capacity by establishing partnerships with top six global pharmaceutical companies including BMS and Roche for a total of nine product lines. Moreover, based on such business performance, Samsung Biologics successfully completed its IPO in November 2016, amidst the keen interest and support of global investors.
“All of our utives and employees have persistently strived to build a global bio CMO company over the past six years,” addressed Dr. Kim, giving the workers credit for the successful development. “Now is the time to take a step forward while the demand for biopharmaceuticals is increasing. It is also a critical moment to compete with other CMOs and pharmaceutical companies that are expanding their production facilities.”
He added to present a new vision, “Do not be content with being just a CMO champion. Instead we need to become a “game changer” by pushing for customer-oriented innovation so as to enable global biopharmaceutical companies’ utilization of CMO production to increase from the current level of 25% to 50% or more.”
The framing completion ceremony of Plant 3 was held on April 20 (Thu) to provide encouragement to all the workers involved in Plant 3’s construction, wish their safety, and pledge successful completion of the construction work.
Plant 3, construction of which is currently 75% complete, will achieve mechanical completion by the end of this year. When the construction of Plant 3 is completed, Samsung Biologics will become the number one CMO in 2018 in terms of production capacity.
Samsung Biologics’ Sixth Anniversary Ceremony
- Held on April 21 at Samsung Biologics’ headquarters in Songdo, Incheon, with 300 utives and employees present
- Dr. Tae Han Kim, President and CEO, introduced the vision of becoming a “game changer to expand the CMO market”
Samsung Biologics (CEO: Tae Han Kim) held its sixth anniversary ceremony on April 21 (Fri), 2017 at its headquarters in Songdo, Incheon.
With 300 utives and employees attending the event, the ceremony started with a commemorative speech by Dr. Kim, who has led Samsung Biologics for 6 years since its establishment, followed by an awards ceremony for exemplary employees who have contributed to the development of the company.
In 2010, Samsung group designated the biopharmaceutical industry as one of five new businesses, and established Samsung Biologics the next year in 2011.
Right after its establishment, Samsung Biologics began constructing its Plant 1 which has a capacity of 30,000L. Then in 2013, Samsung Biologics began construction of its Plant 2, which has a capacity of 150,000L, marking the world’s largest plant in capacity, breaking the world record in the biopharmaceutical industry in terms of production capacity, cost and construction period. In 2015, Samsung Biologics sought to break the world record once again by beginning construction of its Plant 3 with a capacity of 180,000L.
Samsung Biologics has become the largest CMO company in the world by ceaselessly establishing three plants with intensive investment over the past six years. Furthermore, by acquiring quality approvals from the U.S., Europe, and Japan, the top three global pharmaceutical markets, its competitive edge in terms of quality has been proven worldwide in a short period of time.
Based on its quantitative and qualitative growth, the company has sustainably expanded its production capacity by establishing partnerships with top six global pharmaceutical companies including BMS and Roche for a total of nine product lines. Moreover, based on such business performance, Samsung Biologics successfully completed its IPO in November 2016, amidst the keen interest and support of global investors.
“All of our utives and employees have persistently strived to build a global bio CMO company over the past six years,” addressed Dr. Kim, giving the workers credit for the successful development. “Now is the time to take a step forward while the demand for biopharmaceuticals is increasing. It is also a critical moment to compete with other CMOs and pharmaceutical companies that are expanding their production facilities.”
He added to present a new vision, “Do not be content with being just a CMO champion. Instead we need to become a “game changer” by pushing for customer-oriented innovation so as to enable global biopharmaceutical companies’ utilization of CMO production to increase from the current level of 25% to 50% or more.”
The framing completion ceremony of Plant 3 was held on April 20 (Thu) to provide encouragement to all the workers involved in Plant 3’s construction, wish their safety, and pledge successful completion of the construction work.
Plant 3, construction of which is currently 75% complete, will achieve mechanical completion by the end of this year. When the construction of Plant 3 is completed, Samsung Biologics will become the number one CMO in 2018 in terms of production capacity.